Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | SLC34A1 | Q06495 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603486 | 0.87 | GRM5 (0.56) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL20075545 | 0.86 | LMNA (0.53) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL15750737 | 0.82 | ALDH1A1 (0.56) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL20075543 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL4826329 | 0.79 | SLC34A1 (0.55) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL30130669 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LMNAGABRA2GABRB2MAPT | |
| SCHEMBL20551036 | 0.77 | TSHR (0.56) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL18003522 | 0.76 | GABRA2 (0.62) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL23130747 | 0.75 | GABRA2 (0.54) | ALDH1A1LMNANPSR1NPC1RAB9A | |
| SCHEMBL7973221 | 0.75 | ALDH1A1 (0.51) | ALDH1A1LMNANPC1RAB9AGABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | ALDH1A1 266/4885LMNA 3874/4885NPSR1 67/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | ALDH1A1 266/4885LMNA 3874/4885NPSR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.